🇺🇸 PASIREOTIDE PAMOATE in United States

FDA authorised PASIREOTIDE PAMOATE on 15 December 2014 · 70 US adverse-event reports

Marketing authorisations

FDA — authorised 15 December 2014

  • Application: NDA203255
  • Marketing authorisation holder: RECORDATI RARE
  • Local brand name: SIGNIFOR LAR KIT
  • Indication: FOR SUSPENSION — INTRAMUSCULAR
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Pressure Increased — 8 reports (11.43%)
  2. Cough — 8 reports (11.43%)
  3. Drug Ineffective — 8 reports (11.43%)
  4. Nasopharyngitis — 8 reports (11.43%)
  5. Oropharyngeal Pain — 8 reports (11.43%)
  6. Anaemia — 6 reports (8.57%)
  7. Blood Glucose Increased — 6 reports (8.57%)
  8. Concomitant Disease Aggravated — 6 reports (8.57%)
  9. Diabetes Mellitus — 6 reports (8.57%)
  10. Diarrhoea — 6 reports (8.57%)

Source database →

PASIREOTIDE PAMOATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is PASIREOTIDE PAMOATE approved in United States?

Yes. FDA authorised it on 15 December 2014; FDA has authorised it.

Who is the marketing authorisation holder for PASIREOTIDE PAMOATE in United States?

RECORDATI RARE holds the US marketing authorisation.